ERAS for Gastric Cancer Patients After NACT - Trial NCT06365814
Access comprehensive clinical trial information for NCT06365814 through Pure Global AI's free database. This phase not specified trial is sponsored by The Affiliated Hospital of Qingdao University and is currently Completed. The study focuses on Gastric Cancer. Target enrollment is 252 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Affiliated Hospital of Qingdao University
Timeline & Enrollment
N/A
Oct 01, 2023
Apr 01, 2024
Primary Outcome
postoperative infectious complications
Summary
Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more
 vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in
 surgical patients aiming at reducing stress responses. However, whether this approach is safe
 and feasible for gastric cancer patients received minimally invasive radical gastrectomy
 after NACT remained determined. So, the objective of this study is to investigate the effects
 of ERAS for this special group of gastric cancer patients.
 
 Materials and Methods: The data of gastric cancer patients who underwent minimally invasive
 radical gastrectomy after NACT were collected in this retrospective cohort study. Patients
 were divided into an ERAS group and a conventional group based on whether they received
 perioperative ERAS management. Propensity score matching was conducted to eliminate bias.
 Pre- and postoperative inflammatory and nutritional marker levels, postoperative
 complications, recovery indices and 3-year OS and RFS were observed.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06365814
Non-Device Trial